A phase 1B/2 study of the CD123-targeting antibody-drug conjugate pivekimab sunirine (IMGN632) in combination with venetoclax (VEN) and azacitidine (AZA) for patients with CD123-po... by Daver, NG, Montesinos, P, Aribi, A, Martinelli, G, Altman, J, Roboz, G, Wang, ES, Burke, PW, Jeyakumar, D, Walter, RB, DeAngelo, DJ, Erba, HP, Advani, A, Gastaud, L, Thomas, X, Todisco, E, Pemmaraju, N, Mendez, L, de la Fuente, A, Gaidano, G, Curti, A, Boissel, N, Recher, C, Schliemann, C, Vyas, P, Sloss, CM, Wang, J, Malcolm, KA, Zweidler‐McKay, PA, Sweet, KL

AML-262 Pivekimab Sunirine (PVEK, IMGN632) triplet with azacitidine and venetoclax shows broad activity in adverse genetic subsets of relapsed/refractory acute myeloid leukemia and... by Daver, N, Montesinos, P, Aribi, A, Martinelli, G, Altman, JK, Wang, ES, Roboz, GJ, Burke, PW, Gaidano, G, Walter, RB, Thomas, X, Jeyakumar, D, DeAngelo, DJ, Erba, HP, Todisco, E, Begna, K, Advani, A, Gastaud, L, de la Fuente, A, Curti, A, Mendez, LM, Vyas, P, Boissel, N, Vey, N, Recher, C, Longval, T, Platzbecker, U, Kapp-Schwörer, S, Schliemann, C, Konopleva, M, Torres, L, Sallman, DA, Marcucci, G, Marconi, G, Kantarjian, H, Sloss, CM, Malcolm, KE, Zweidler-McKay, PA, Sweet, K